Despite the largest U.S. pharmacy benefit manager (PBM) knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Revenue climbs more than 50% to beat expectations by a wide margin as demand for GLP-1 drugs are still booming Eli Lilly's stock rallies, as Zepbound sales nearly tripled, leading to record revenue ...

Eli Lilly LLY is a dominant player in the cardiometabolic space, all thanks to the encouraging uptake for its blockbuster GLP-1 drugs — Mounjaro (for type II diabetes [T2D]) and Zepbound (for obesity) ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In the year-ago quarter, Lilly recorded ...